NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on NewAmsterdam Pharma, with 10 buy, two strong-buy, one hold and one sell rating. The average 12-month price target is $49.33, well above the stock’s reported $26.90 price.
• Recent analyst actions were mixed but generally positive: Jefferies and RBC maintained outperform/buy-equivalent ratings, while BMO initiated coverage with an outperform rating and a $58 target; RBC trimmed its target to $50.
• The company reported a quarterly loss of $0.52 per share, missing the $0.48 consensus estimate, although revenue of $3.70 million exceeded expectations. Shares were trading below both their 50-day and 200-day moving averages, while insiders sold 210,000 shares over the past quarter.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) has earned an average rating of "Moderate Buy" from the fourteen ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, ten have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $49.3333.

Several research analysts recently weighed in on the stock. Wall Street Zen raised shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. Jefferies Financial Group reissued a "buy" rating and set a $45.00 price target on shares of NewAmsterdam Pharma in a report on Monday, July 20th. BMO Capital Markets started coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They issued an "outperform" rating and a $58.00 price objective on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Finally, Royal Bank Of Canada cut their target price on NewAmsterdam Pharma from $51.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th.

Insider Activity at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 105,000 shares of the company's stock in a transaction on Monday, July 20th. The shares were sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the completion of the transaction, the chief accounting officer owned 24,353 shares in the company, valued at approximately $738,870.02. This represents a 81.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 210,000 shares of company stock valued at $6,713,550 over the last quarter. 12.74% of the stock is currently owned by insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

Large investors have recently made changes to their positions in the company. Farther Finance Advisors LLC boosted its stake in NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company's stock valued at $25,000 after buying an additional 708 shares during the last quarter. Wells Fargo & Company MN increased its stake in NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company's stock worth $32,000 after acquiring an additional 300 shares during the last quarter. KBC Group NV bought a new stake in NewAmsterdam Pharma in the 1st quarter worth approximately $37,000. Navalign LLC purchased a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $46,000. Finally, Empowered Funds LLC purchased a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $85,000. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Trading Down 0.3%

NewAmsterdam Pharma stock opened at $26.90 on Tuesday. The firm has a 50 day moving average of $30.84 and a 200 day moving average of $32.26. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of -12.45 and a beta of 0.10. NewAmsterdam Pharma has a 12-month low of $23.05 and a 12-month high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). The firm had revenue of $3.70 million during the quarter, compared to the consensus estimate of $2.83 million. NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. On average, analysts predict that NewAmsterdam Pharma will post -1.82 EPS for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.